Lipum’s clinical development journey continues in 2023
2022 was the year when the biopharmaceutical company Lipum entered the clinical phase with the drug candidate SOL-116 for the treatment of chronic inflammatory...
Iconovo starts 2023 with negotiations for ICOpre
Iconovo enters the new year with confidence after a rewarding and eventful 2022. During the year, the company moved into new facilities at Ideon...
BioStock Investor Pitch: Spermosens
Swedish Spermosens’ vision is to improve diagnostics within the area of male infertility and thus help improve IVF treatments. Using the company’s JUNO-Checked system...
VILDA – new network for female leaders in life science
In December 2022, Anna Törner, Cecilia Bröms-Thell and Sarah Lidé announced that they are starting a new network for female leaders in life science....
Evaxion receives phase IIb go-ahead from FDA
Evaxion Biotech started 2022 with a green light from the Australian authorities to conduct a phase IIb study with lead drug candidate EVX-01 in...
Spago Nanomedical publishes positive preclinical data
Preclinical data with Spago Nanomedical’s radionuclide therapy concept Tumorad was recently published in the scientific journal ACS Omega. The paper describes the composition, stability...
Chronic pain in focus for CombiGene´s new collaboration
CombiGene has entered into a collaboration agreement with Danish Zyneyro regarding the continued development of treatments for chronic pain conditions – a peptide with...
Alligator Bioscience extends collaboration with Orion Corporation
As Alligator Bioscience makes headways with its clinical development of cancer immunotherapy mitazalimab, the company’s bispecific antibody technology RUBY is also turning heads. Alligator...
BiBBInstruments comments on upcoming patent approval
Swedish medtech BiBBInstruments is developing the world’s first CE-marked endoscopic ultrasound-guided core needle biopsy device – EndoDrill. 2023 gets off to a good start for...
Promore Pharma’s CEO on hopes for 2023
For Solna-based Promore Pharma, 2022 was characterised by steady advancement in the development of its drug candidate ensereptide. During the year, the company carried...
